A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

GLP-1 receptor agonists have gained attention as medications to manage type 2 diabetes and obesity. Drugs such as semaglutide and tirzepatide help regulate blood sugar and reduce appetite, which can ...

Spread the loveAs the popularity of GLP-1 receptor agonists like semaglutide and tirzepatide continues to rise for weight management, emerging research suggests that these medications may come with ...

Medications known as GLP-1 receptor agonists have become some of the most popular treatments for weight loss in recent years. These drugs, originally developed to help people with diabetes control ...

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Drugs that mimic GLP-1 are widely used to treat diabetes and obesity, but it is not fully understood exactly how they produce many of their beneficial effects. Investigators from The Salk Institute ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...